MDS with Ring Sideroblasts
A myelodysplastic syndrome subtype characterized by iron-laden ring sideroblasts in the bone marrow, frequently linked to SF3B1 mutations and often a favorable clinical course.
- SF3B1-associated subtype
- Often favorable, indolent course
- Specialist marrow review available
- Most Common In
- Older adults
- Defining Feature
- Ring sideroblasts ≥15% of marrow erythroid cells
- Typical Course
- Often indolent, frequently SF3B1-mutant
- Advanced Therapies
- Luspatercept, hypomethylating agents
Condition Overview
MDS with ring sideroblasts is a myelodysplastic syndrome subtype defined by the presence of abnormal iron deposits encircling the nucleus of immature red blood cells in the bone marrow, known as ring sideroblasts. This finding is strongly associated with mutations in the splicing gene SF3B1.
Patients typically present with anemia that can be significant, sometimes with relatively preserved white cell and platelet counts. The subtype is often, though not always, associated with a more favorable disease trajectory compared with other forms of MDS, particularly when blast percentage remains low.
Types and Subtypes
MDS with ring sideroblasts is subdivided based on blast percentage and the number of affected cell lineages.
Symptoms and Signs
Symptoms are largely driven by anemia, which can be more pronounced than in some other lower-risk MDS subtypes.
Causes and Risk Factors
The development of ring sideroblasts relates to disrupted iron metabolism within developing red blood cells, most often driven by acquired splicing gene mutations.
Diagnosis and Investigations
Diagnosis hinges on identifying ring sideroblasts on bone marrow iron staining alongside confirmatory molecular testing.
Staging and Risk Groups
Risk in MDS with ring sideroblasts is assessed using the IPSS-R and IPSS-M systems, incorporating blast percentage, cytogenetics, and molecular findings.
Standard Treatment
Treatment is tailored to anemia severity, transfusion dependence, and overall risk category.
Advanced & Emerging Therapies
Beyond standard supportive and luspatercept therapy, ongoing research targets refractory anemia and higher-risk transformation in this subtype.
Targeted
Luspatercept
An approved erythroid maturation agent specifically beneficial in ring sideroblast MDS.
Cellular Therapy
Allogeneic stem cell transplantation
Considered for eligible higher-risk or treatment-refractory patients.
Precision Medicine
Splicing-pathway targeted agents
Investigational compounds targeting SF3B1-related splicing dysregulation are under study.
Biomarkers & Precision Medicine
Molecular testing in this subtype helps confirm diagnosis and predict treatment response.
When to Seek 2nd Opinion
Specialist input can help clarify diagnosis and treatment sequencing in this subtype.
Clinical Trials & Research
Prognosis & Outcomes
Outcomes in MDS with ring sideroblasts are often favorable, particularly in SF3B1-mutant, low blast percentage disease.
Supportive Care
Supportive care addresses the chronic anemia and transfusion-related issues common in this subtype.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with MDS and ring sideroblasts get expert review of bone marrow and SF3B1 molecular testing, coordinates second opinions, and connects patients with specialists experienced in luspatercept therapy and transplant decision-making.
Get a free case reviewFrequently Asked Questions
It is a myelodysplastic syndrome subtype defined by abnormal iron deposits, called ring sideroblasts, surrounding the nucleus of developing red blood cells in the bone marrow.
The majority of cases carry an acquired mutation in the SF3B1 gene, which is strongly associated with ring sideroblast formation and a generally favorable course.
Luspatercept is an approved erythroid maturation agent that can reduce transfusion needs in transfusion-dependent patients with this subtype who have not responded to other anemia treatments.
When SF3B1-mutant and associated with low blast percentage, this subtype often follows a more indolent course, though outcomes vary with cytogenetics and other mutations.
Diagnosis requires bone marrow iron staining to identify ring sideroblasts, along with molecular testing for SF3B1 and other relevant mutations.
Progression is possible but generally less frequent than in higher-risk MDS subtypes, especially in SF3B1-mutant, low blast disease.
A concurrent TP53 mutation is associated with a less favorable course and may prompt earlier consideration of transplant.
Monitoring frequency depends on risk category and treatment response, typically ranging from every few weeks to every few months.
Transfusion support, iron chelation when needed, and fatigue management strategies are central to ongoing care.
Yes. CancerFax helps patients obtain expert review of bone marrow and molecular reports, coordinate second opinions, and connect with specialists experienced in luspatercept therapy and transplant pathways, including international coordination where needed.
Get Expert Guidance for MDS with Ring Sideroblasts
Send your bone marrow and molecular reports for specialist review and explore your treatment options with confidence.